Abstract

The COVID-19 pandemic is the most recent of numerous pathogenic viral pandemics that have posed risks to global health. Its exponentially expanding global transmission is placing pressure on the global health system. There are currently a large number of COVID-19 candidate vaccines on the market, and there is fierce worldwide competition to obtain the most vaccinations for each nation. The main objective among several nations during the exceptional COVID-19 epidemic has been to build herd immunity through the planning of large-scale vaccination efforts. However, the availability of vaccines has been a challenge for developing countries. However, there are strains in the world's vaccine manufacturing as a result of the high demand. This international effort aims to develop plant-based heterologous expression systems, virus-like particles (VLPs)-vaccines, antiviral drugs, a rapid supply of antigen-antibodies for detecting kits, and plant-origin bioactive compounds that boost immunity and provide tolerance to fight against virus infection, also includes the use of a plant biotechnology-based expression system for vaccine production. Due to possible benefits including low cost, high manufacturing volume, and physicochemical characteristics, the idea of a plant-based vaccination has gained more and more momentum in recent years. By utilising local commodities, we suggest plant-based vaccines as an appealing alternative to widespread and inexpensive vaccination methods against COVID-19 in this review. Additionally, we discussed the processes of action, necessary standards, and prospects for applying unique biotechnology tools in near future.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call